Gilead Sciences

GILD

----

2026-W372026-09-07

GILD.US Weekly Report · 2026-W37

Overview

Gilead Sciences stock came under pressure this week, declining 4.81% week-on-week. The primary headwind stems from two sources: first, Q2 earnings reported a significant EPS loss of -$8.45, substantially below consensus expectations of $9.13, triggering concerns about profit delivery; second, major institutional capital flowed outward this week while retail investors continued to exit, signaling weak near-term confidence in fundamentals. Paradoxically, valuation metrics sit at multi-year lows, and institutional ratings remain constructive overall, creating a classic “undervalued yet sold-off” dynamic.

Price Action

This week’s close of $143.72 represents a 4.81% decline from last Friday’s (Sep 4) close of $150.995. Intraday volatility remained muted, with a range between $145.99 high and $143.50 low, yielding a 1.71% amplitude. Volume contracted notably to 4.20 million shares daily against a 60-day median of approximately 5.96 million, reflected in a turnover rate of 0.34%.

The candlestick pattern shows a consolidation amid selling pressure, marked by shrinking volume rather than capitulative breakdown. This low-volume retreat typically surfaces during periods of conflicting sentiment or anticipation of fresh catalysts.

Valuation and Earnings

Valuation Positioning

The current price-to-book (P/B) ratio of 15.18x sits at the 1.54th percentile over the past 5 years—among the most depressed levels on record. While this represents a premium relative to sector median P/B of 1.93x, the historical perspective reveals current pricing within the cheapest quintile of its recent range.

Earnings Delivery

Q2 2026 results disappointed sharply:

EPS of -$8.45, a dramatic reversal from Q1’s $1.61 and a 641.67% year-over-year decline versus Q2 2025’s $1.56
Operating revenue of $7.803 billion grew 10.18% year-over-year but contracted 11.9% sequentially from Q1
Net profit swung to -$10.496 billion with a net margin of -134.51%; Q1 had recorded $2.021 billion in profit

Consensus EPS forecast (tracking 85 institutions) stands at $9.125. Q2’s -$8.45 miss represents a shortfall exceeding 190%. This earnings disappointment is the fundamental driver of this week’s price weakness. ROE crashed to -237.57%, confirming severe single-quarter distress.

Examining the trailing six-quarter trajectory, Q1 2026, Q4 2025, and Q3 2025 had maintained consecutive profitability before Q2’s unexpected collapse, disrupting recovery momentum and resetting market expectations downward.

Capital Flows

This week’s capital structure reveals institutional retreat coupled with retail capitulation:

Institutional (Large) flows: Buy $210.13 vs. Sell $43.14; net buy ratio of only 82.7%, indicating net outflow
Medium accounts: Buy $1,237.41 vs. Sell $1,132.83; net buy ratio 109.2%, demonstrating modest support
Retail (Small): Buy $3,421.91 vs. Sell $4,324.26; net buy ratio 79.1%, reflecting sustained liquidation

The aggregate picture resembles classic “institutions turn cautious while retail panics”—major players are not aggressively dumping but are net sellers, suggesting guarded near-term views. Medium-tier capital’s marginal net inflow hints at “value buying” tactics, though insufficient in magnitude to offset larger outflows. Retail steadily reduces exposure.

Institutional Ratings

Current analyst consensus (35 rated positions) breaks down as:

Strong Buy: 15
Buy: 6
Hold: 6
Underperform: 1
Consensus recommendation: Buy, ranked 6th among 506 biotechnology peers

Median price target of $158.15 implies 10.0% upside from current levels; high target $180, low $123. Last update: Sep 10, 2026—only one day prior.

Rating Lag Risk: This constructive view was refreshed a mere day post-earnings disappointment. Given the magnitude of the miss, a wave of subsequent downgrades remains plausible. Historical precedent suggests analyst revisions typically trail major earnings surprises by days to weeks.

This Week’s News

From 30 items this week, the salient themes emerge:

Drug Approvals and Regulatory Setbacks: The UK’s NICE rejected coverage of Gilead’s twice-yearly lenacapavir formulation, signaling pricing/cost-effectiveness hurdles. Contemporaneously, Sunlenca and new once-daily HIV tablet advances proceed, highlighting divergence between pipeline progress and market access outcomes.
R&D Expansion: Launch of a state-of-the-art US research center signals commitment to next-generation HIV and oncology pipelines entering execution phase. While underscoring mid-term growth potential, it offers no near-term profit contribution.
Management Equity Sales: CEO Daniel O’Day disposed of 15,000 shares ($2.23 million). In a context of stock weakness and freshly-updated analyst ratings, insider selling often signals management confidence erosion.

Top News Items (by relevance):

Summary

This week’s downside pressure stems from earnings misfire rather than fundamental deterioration—the -$8.45 Q2 EPS represents an isolated quarterly aberration (prior quarters Q1, Q4, Q3 showed profitability), likely driven by one-off charges or non-recurring items rather than operational breakdown.

Central Paradox: Valuation at historic lows (P/B at 1.54th percentile over 5 years) + constructive institutional consensus (21 positive vs. 6 neutral-to-negative) + outflowing institutional capital = market repricing as if “bad news insufficiently reflected.” This constellation suggests continued near-term pressure but also signals substantial upside if Q3 or subsequent results restore profitability.

Key watch points ahead:

Q3 earnings versus consensus EPS guidance of $9.125
Commercial traction of Sunlenca and new formulations
Magnitude and direction of forthcoming analyst revisions
Institutional capital flow reversion

This report is based on LongBridge data, updated as of September 12, 2026.